Developer docs
API playgroundTry for free, no card

Search company profiles

SCM Lifescience

Full company profile

uuid0002d18

Namestring
SCM Lifescience
Legal namestring
에스씨엠생명과학 주식회사
Company typeenum
Public
Founded yearint
2014
Descriptiontext

SCM Lifescience (에스씨엠생명과학 주식회사) is a South Korean clinical-stage biotechnology company founded in 2014 and headquartered in Incheon Songdo, focused on developing high-purity stem cell therapies for rare and intractable diseases. The company's scientific foundation is its proprietary Subfractionation Culturing Method (층분리배양법), a source technology for isolating and culturing clonal mesenchymal stem cell lines at higher purity (>95%) and colony-forming efficiency (5x conventional methods) than gradient centrifugation alternatives. This technology underpins a pipeline of allogeneic bone marrow-derived stem cell candidates — SCM-AGH for moderate-to-severe atopic dermatitis (Phase 2 completed, results published in JACI), SCM-AGH for acute pancreatitis (Phase 2a completed, results in Gastroenterology), and SCM-CGH for chronic graft-versus-host disease (Phase 2 ongoing, Korea's 23rd orphan drug designation). The company also operates an immune cell therapy portfolio via its US subsidiary CoImmune, including CARCIK-CD19 (76.2% complete remission in Phase 1/2) and CMN-001 dendritic cell vaccine (FDA-approved Phase 2b in metastatic renal cell carcinoma). Manufacturing capability is anchored on 3D bioreactor mass production technology developed with PBS Biotech and human platelet lysate (hPL)-based culture media replacing animal-derived serum.

The company operates a dual business model. On the pharmaceutical side, it pursues B2B licensing-out of pipeline candidates (notably to Handok for atopic dermatitis in Korea), contract manufacturing services (CHA Biotech CMO partnership), and equity-linked commercialization deals. On the consumer side, it sells IRORO and the newly launched Enseria cosmetics brands — containing proprietary CXCL1 protein for haircare and bone marrow-derived stem cell culture media for skincare — through exclusive regional distributors across Vietnam, Hong Kong, Japan, Malaysia, and China, with initial China export contracts valued at ~4 billion KRW. The company is publicly listed on KOSDAQ (ticker 298060), holds 80+ patents across 15+ jurisdictions, and has pursued international expansion through acquisitions of CoImmune (USA, 2020), Formula (Italy, 2020), Pungjeon Pharmaceutical (2025), and Dermassimo (2025). SCM Lifescience is currently undergoing operational restructuring under a CEO transition completed in October 2024, accompanied by a 2026 stock consolidation.

Short descriptiontext

SCM Lifescience is a South Korean clinical-stage biotechnology company developing allogeneic stem cell therapies for rare and intractable diseases (atopic dermatitis, acute pancreatitis, GVHD) using its proprietary Subfractionation Culturing Method, while also distributing IRORO and Enseria cosmetics brands across Asian markets through exclusive regional partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersIncheon, South Korea
HQ citystring
Incheon
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
stem cell therapy, cell therapy products, regenerative medicine, cosmeceutical products, contract manufacturing
Industry5 codes
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Cell Therapy
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Stem Cell Therapy Licensing
TypeLicensing Royalties
Description

Revenue from licensing out stem cell therapy candidates (SCM-AGH for atopic dermatitis, acute pancreatitis, GVHD) to pharmaceutical partners. Deal with Handok for domestic licensing, with ongoing technology transfer negotiations with global pharma companies.

scmlifescience.com
2Cosmetic Products
TypeHardware Sales
Description

Revenue from skincare and haircare products under brands IRORO and Enserea, sold through partner distributors in Vietnam, Hong Kong, Japan, Malaysia, and China, with exports of approximately 4 billion KRW in initial contracts.

scmlifescience.com
3Contract Manufacturing (CMO)
TypeProfessional Services
Description

CMO services for bone marrow-derived cell therapy products, including partnerships with CHA Biotech and PBS Biotech for manufacturing process development.

scmlifescience.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1IRORO (이로로)
Description

Skincare and haircare brand featuring stem cell-derived culture media and CXCL1 protein for hair loss prevention

scmlifescience.com
+2 more records
Core offering1 text field

SCM Lifescience develops and supplies high-purity, high-efficacy allogeneic stem cell therapies for intractable diseases including atopic dermatitis (SCM-AGH), acute pancreatitis (SCM-AGH), and chronic graft-versus-host disease (SCM-CGH), plus immune cell therapies (CARCIK-CD19, CMN-001) via its CoImmune subsidiary. The company also operates consumer cosmeceutical brands IRORO and Enseria featuring stem cell culture media and CXCL1 protein ingredients, and provides contract manufacturing (CMO) services for cell therapy products.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Statistically significant EASI-50 response at Week 12 in moderate-to-severe atopic dermatitis Phase 1/2 trial
+2 more records
Product overview1 text field

SCM Lifescience is a bio company providing high-quality (high-purity + high-efficacy) cell therapy products for treating incurable diseases. The company operates two main business divisions: (1) Stem Cell Therapeutics including SCM-AGH for atopic dermatitis, acute pancreatitis, and graft-versus-host disease, plus CAR-CIK and dendritic cell cancer immunotherapies through its CoImmune affiliate; and (2) Cosmeceuticals including the Iroro and Enseria skincare brands containing proprietary bone marrow-derived stem cell culture medium and CXCL1 proteins. The portfolio is underpinned by the company's proprietary Subfractionation Culturing Method technology for high-purity stem cell isolation and a 3D Bioreactor-based mass production manufacturing system.

Product and service9 records
1SCM-AGH (Atopic Dermatitis Treatment)
CategoryCell Therapy - Stem Cell Therapeutics
Description

Allogeneic bone marrow-derived clonal mesenchymal stem cell therapy for moderate-to-severe atopic dermatitis. Produced using the company's proprietary Subfractionation Culturing Method for high-purity stem cell isolation. Phase 2 clinical trial completed with statistically significant EASI-50/75/90 responses published in Journal of Allergy and Clinical Immunology.

2SCM-AGH (Acute Pancreatitis Treatment)
CategoryCell Therapy - Stem Cell Therapeutics
Description

Allogeneic bone marrow-derived clonal mesenchymal stem cell therapy for moderate-to-severe acute pancreatitis. Designated as rare drug by Korea's Ministry of Food and Drug Safety in 2020. Phase 2a clinical trial completed with results published in Gastroenterology.

3SCM-CGH (Chronic Graft-versus-Host Disease Treatment)
CategoryCell Therapy - Stem Cell Therapeutics
Description

Allogeneic bone marrow-derived clonal mesenchymal stem cell therapy for chronic graft-versus-host disease (cGvHD). Designated as Korea's 23rd orphan drug in development stage from the Ministry of Food and Drug Safety in 2019.

4CARCIK-CD19
CategoryCell Therapy - Immune Cell Therapy
Description

Allogeneic, virus-free CAR-CIK (Cytokine-Induced Killer) cell therapy for acute lymphocytic leukemia (ALL). Uses the Sleeping Beauty transfer factor system. Phase 1/2 clinical trial demonstrated a 76.2% complete remission rate. Developed through the CoImmune (USA) subsidiary.

5CMN-001
CategoryCell Therapy - Immune Cell Therapy
Description

mRNA-based dendritic cell anti-cancer vaccine for metastatic renal cell carcinoma. Uses tumor RNA electroporated dendritic cells. In Phase 2 clinical trial with 90 patients. Developed through the CoImmune (USA) subsidiary.

6IRORO Cosmetics Brand
CategoryCosmeceuticals
Description

Skincare and haircare brand containing proprietary ingredients including CXCL1 hair loss prevention protein and human bone marrow-derived stem cell culture medium. Includes IRORO Nuvon (anti-aging), IRORO AD Intensive Cream (skin barrier), and IRORO DierScalp (haircare) product lines. Trademarks registered in Japan, Korea, and Hong Kong.

7Enseria (엔세리아) Cosmetics Brand
CategoryCosmeceuticals
Description

Premium skincare brand launched in February 2025 targeting middle-aged and older consumers with an elegant and sophisticated image, positioned alongside the IRORO brand for a dual-brand global marketing strategy.

8SCMVial Research Cells
CategoryResearch Cell Products
Description

Research-use stem cell product using the proprietary Subfractionation Culturing Method. Enables consistent quality cells from basic research through clinical stages for stem cell therapy research applications.

9Contract Manufacturing (CMO) Services
CategoryManufacturing Services
Description

CMO services for bone marrow-derived cell therapy products, including partnerships with CHA Biotech and PBS Biotech for manufacturing process development using the company's 3D Bioreactor mass production technology.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership18 partners
1Pungjeon Pharmaceutical (풍전약품)
Strategic tierCoreTypeOthersAnnounced on2025-07-01
Description

Acquisition completed in July 2025 as part of company's M&A strategy for rapid cGMP and global pipeline expansion.

scmlifescience.com
2Dermassimo (주식회사 더마시모)
Strategic tierCoreTypeOthersAnnounced on2025-07-01
Description

Acquisition completed in July 2025 to expand cosmetics business and secure additional pipeline.

scmlifescience.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-21
Description

MOU for joint development of pet cell therapy products. Combining SCM Lifescience's stem cell technology with Onhill's pet healthcare platform expertise and market network for innovative cell therapy development for companion animals.

4Regina Skin Medical Company Ltd.
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-10-14
Description

Chinese state-owned enterprise partnership for exclusive distribution of IRORO cosmetics brand (skincare and haircare products) across China. Initial export contract of approximately 4 billion KRW. Products include CXCL1-based haircare and cell-activated culture media skincare lines.

scmlifescience.com
5Isblanc (이즈블랑)
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-09-01
Description

Exclusive licensing agreement for IRORO Nuvon newborn skincare products distribution in Japan, with launch preparations underway.

scmlifescience.com
6Cherry Trading Limited Company
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-07-01
Description

Exclusive distribution agreement for all IRORO products in Vietnam. Vietnamese government approval received for cosmetics launch in Ho Chi Minh City and Hanoi.

scmlifescience.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-07-01
Description

Haircare product supply contract with Malaysian state-owned pharmaceutical company. Halal certification obtained for IRORO products. Distribution through Duopharma Consumer Healthcare subsidiary.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-01
Description

Joint business agreement for strategic technology commercialization. Collaboration on autoimmune disease stem cell multi-process platform development (2024 Pan-Ministry Regenerative Medical Technology Development Project).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-01
Description

Equity investment and license-out contract for severe atopic dermatitis stem cell treatment. Handok expected to announce Phase 3 clinical trial participation decision.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-01-01
Description

Partnership for 3D bioreactor mass production process development. Global innovation company for cell therapy manufacturing process achieving groundbreaking cell yield rates.

11TheraImmune
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

MOU for joint development of cell therapy for autoimmune diseases.

scmlifescience.com
12CoImmune Inc. (USA)
Strategic tierCoreTypeOthersAnnounced on2020-01-01
Description

US subsidiary acquired for dendritic cell vaccine and CAR-CIK cell therapy development. FDA-approved Phase 2b trial for metastatic renal cell carcinoma.

scmlifescience.com
Strategic tierMinorTypeOthersAnnounced on2020-01-01
Description

Italian subsidiary acquired as part of European market expansion through M&A.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

MOU for joint development of 3D bioprinting integrated treatment.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

MOU for joint development of high-purity mesenchymal stem cell-derived exosomes.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

MOU for joint research on next-generation cell therapy products and biomarkers.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

MOU for gene-inserted stem cell therapy development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Joint research agreement for stem cell therapy using cell sheet technology. NIMS Award 2022 recipient for tissue engineering research using SCM's source technology.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Korean biotech commercializing Cartistem (allogeneic MSC therapy for knee cartilage) and PneumoStem. Directly comparable as a Korean MSC therapy company with similar regulatory pathway, customer base (hospitals), and orphan/rare disease focus.

2Corestem
TypeDirect peer
Description

Korean biotech developing Neuronata-R (autologous bone marrow MSC therapy for ALS). Direct peer with same source material (bone marrow-derived MSCs), Korean regulatory focus, and rare intractable disease positioning.

TypeDirect peer
Description

Australian commercial-stage MSC therapy company with Remestemcel-L for pediatric SR-aGVHD and Revascor for heart failure. Closest international peer with comparable allogeneic MSC platform, GVHD indication overlap, and regulatory/clinical pathway.

4Pluristem Therapeutics
TypeDirect peer
Description

Israel-based company developing PLX cell therapy products from placenta-derived mesenchymal-like adherent stromal cells. Comparable allogeneic, off-the-shelf cell therapy approach targeting inflammatory and ischemic conditions with similar licensing-based commercialization model.

5Cynata Therapeutics
TypeDirect peer
Description

Australian clinical-stage company developing CYP-001 and other iPSC-derived MSC therapies for GvHD and osteoarthritis. Comparable allogeneic MSC platform with similar disease focus and partnership-driven development model.

6Athersys
TypeDirect peer
Description

US-based clinical-stage company developing MultiStem (allogeneic bone marrow-derived MSC therapy) for stroke, ARDS, and GvHD. Direct peer with comparable source material, allogeneic platform, and overlapping GvHD indication.

TypeDirect peer
Description

Korean biotech developing stem cell therapies including osteoarthritis and atopic dermatitis applications. Direct Korean peer with overlapping MSC-derived therapies and similar consumer/clinical cosmetics hybrid business model.

TypeDirect peer
Description

Korean biotech with stem cell and cord blood banking operations, CMO services, and CAR-T pipeline. SCM's CMO partner and most operationally comparable Korean cell therapy company with similar manufacturing focus.

TypeDirect peer
Description

US-based clinical-stage cell therapy company developing SPEAR T-cell receptor therapies for solid tumors. Comparable to SCM's CoImmune-acquired CARCIK-CD19 and CMN-001 programs in cell-based cancer immunotherapy approach.

TypeBroad incumbent
Description

South Korea's largest biopharmaceutical company, biosimilars leader, with expanding cell therapy and biosimilar pipeline. Established Korean biopharma incumbent providing market context, comparable regulatory environment, and potential as a strategic acquirer or partner.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SCM Lifescience

Biopharmaceutical Cell Therapyscmlifescience.com

SCM Lifescience is a South Korean clinical-stage biotechnology company developing allogeneic stem cell therapies for rare and intractable diseases (atopic dermatitis, acute pancreatitis, GVHD) using its proprietary Subfractionation Culturing Method, while also distributing IRORO and Enseria cosmetics brands across Asian markets through exclusive regional partners.

What SCM Lifescience does

SCM Lifescience (에스씨엠생명과학 주식회사) is a South Korean clinical-stage biotechnology company founded in 2014 and headquartered in Incheon Songdo, focused on developing high-purity stem cell therapies for rare and intractable diseases. The company's scientific foundation is its proprietary Subfractionation Culturing Method (층분리배양법), a source technology for isolating and culturing clonal mesenchymal stem cell lines at higher purity (>95%) and colony-forming efficiency (5x conventional methods) than gradient centrifugation alternatives. This technology underpins a pipeline of allogeneic bone marrow-derived stem cell candidates — SCM-AGH for moderate-to-severe atopic dermatitis (Phase 2 completed, results published in JACI), SCM-AGH for acute pancreatitis (Phase 2a completed, results in Gastroenterology), and SCM-CGH for chronic graft-versus-host disease (Phase 2 ongoing, Korea's 23rd orphan drug designation). The company also operates an immune cell therapy portfolio via its US subsidiary CoImmune, including CARCIK-CD19 (76.2% complete remission in Phase 1/2) and CMN-001 dendritic cell vaccine (FDA-approved Phase 2b in metastatic renal cell carcinoma). Manufacturing capability is anchored on 3D bioreactor mass production technology developed with PBS Biotech and human platelet lysate (hPL)-based culture media replacing animal-derived serum.

The company operates a dual business model. On the pharmaceutical side, it pursues B2B licensing-out of pipeline candidates (notably to Handok for atopic dermatitis in Korea), contract manufacturing services (CHA Biotech CMO partnership), and equity-linked commercialization deals. On the consumer side, it sells IRORO and the newly launched Enseria cosmetics brands — containing proprietary CXCL1 protein for haircare and bone marrow-derived stem cell culture media for skincare — through exclusive regional distributors across Vietnam, Hong Kong, Japan, Malaysia, and China, with initial China export contracts valued at ~4 billion KRW. The company is publicly listed on KOSDAQ (ticker 298060), holds 80+ patents across 15+ jurisdictions, and has pursued international expansion through acquisitions of CoImmune (USA, 2020), Formula (Italy, 2020), Pungjeon Pharmaceutical (2025), and Dermassimo (2025). SCM Lifescience is currently undergoing operational restructuring under a CEO transition completed in October 2024, accompanied by a 2026 stock consolidation.

SCM Lifescience firmographics

Firmographics
Name
SCM Lifescience
Legal name
에스씨엠생명과학 주식회사
Website
https://scmlifescience.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
SCM Lifescience is a South Korean clinical-stage biotechnology company developing allogeneic stem cell therapies for rare and intractable diseases (atopic dermatitis, acute pancreatitis, GVHD) using its proprietary Subfractionation Culturing Method, while also distributing IRORO and Enseria cosmetics brands across Asian markets through exclusive regional partners.
Ownership category
akta.pro rank

SCM Lifescience industry classification

Industry
Product category
Biopharmaceutical Cell Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Stem cell therapy
  • Cell therapy products
  • Regenerative medicine
  • Cosmeceutical products
  • Contract manufacturing

Where SCM Lifescience is headquartered

Location

Headquarters

HQ city
Incheon
HQ country
South Korea
HQ region
Asia

Offices4 records

Markets served

SCM Lifescience business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Stem Cell Therapy Licensing: Revenue from licensing out stem cell therapy candidates (SCM-AGH for atopic dermatitis, acute pancreatitis, GVHD) to pharmaceutical partners. Deal with Handok for domestic licensing, with ongoing technology transfer negotiations with global pharma companies.
  2. Cosmetic Products: Revenue from skincare and haircare products under brands IRORO and Enserea, sold through partner distributors in Vietnam, Hong Kong, Japan, Malaysia, and China, with exports of approximately 4 billion KRW in initial contracts.
  3. Contract Manufacturing (CMO): CMO services for bone marrow-derived cell therapy products, including partnerships with CHA Biotech and PBS Biotech for manufacturing process development.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

SCM Lifescience product offering

Product offering

Core offering

SCM Lifescience develops and supplies high-purity, high-efficacy allogeneic stem cell therapies for intractable diseases including atopic dermatitis (SCM-AGH), acute pancreatitis (SCM-AGH), and chronic graft-versus-host disease (SCM-CGH), plus immune cell therapies (CARCIK-CD19, CMN-001) via its CoImmune subsidiary. The company also operates consumer cosmeceutical brands IRORO and Enseria featuring stem cell culture media and CXCL1 protein ingredients, and provides contract manufacturing (CMO) services for cell therapy products.

Product overview

SCM Lifescience is a bio company providing high-quality (high-purity + high-efficacy) cell therapy products for treating incurable diseases. The company operates two main business divisions: (1) Stem Cell Therapeutics including SCM-AGH for atopic dermatitis, acute pancreatitis, and graft-versus-host disease, plus CAR-CIK and dendritic cell cancer immunotherapies through its CoImmune affiliate; and (2) Cosmeceuticals including the Iroro and Enseria skincare brands containing proprietary bone marrow-derived stem cell culture medium and CXCL1 proteins. The portfolio is underpinned by the company's proprietary Subfractionation Culturing Method technology for high-purity stem cell isolation and a 3D Bioreactor-based mass production manufacturing system.

Differentiator

Problem solved

Functional benefit

Brands

  • IRORO (이로로): Skincare and haircare brand featuring stem cell-derived culture media and CXCL1 protein for hair loss prevention
  • Enseria (엔세리아)
  • Iroro Nuvon (이로로 뉴본)

Products and services

  • SCM-AGH (Atopic Dermatitis Treatment) Allogeneic bone marrow-derived clonal mesenchymal stem cell therapy for moderate-to-severe atopic dermatitis. Produced using the company's proprietary Subfractionation Culturing Method for high-purity stem cell isolation. Phase 2 clinical trial completed with statistically significant EASI-50/75/90 responses published in Journal of Allergy and Clinical Immunology.
  • SCM-AGH (Acute Pancreatitis Treatment) Allogeneic bone marrow-derived clonal mesenchymal stem cell therapy for moderate-to-severe acute pancreatitis. Designated as rare drug by Korea's Ministry of Food and Drug Safety in 2020. Phase 2a clinical trial completed with results published in Gastroenterology.
  • SCM-CGH (Chronic Graft-versus-Host Disease Treatment) Allogeneic bone marrow-derived clonal mesenchymal stem cell therapy for chronic graft-versus-host disease (cGvHD). Designated as Korea's 23rd orphan drug in development stage from the Ministry of Food and Drug Safety in 2019.
  • CARCIK-CD19 Allogeneic, virus-free CAR-CIK (Cytokine-Induced Killer) cell therapy for acute lymphocytic leukemia (ALL). Uses the Sleeping Beauty transfer factor system. Phase 1/2 clinical trial demonstrated a 76.2% complete remission rate. Developed through the CoImmune (USA) subsidiary.
  • CMN-001 mRNA-based dendritic cell anti-cancer vaccine for metastatic renal cell carcinoma. Uses tumor RNA electroporated dendritic cells. In Phase 2 clinical trial with 90 patients. Developed through the CoImmune (USA) subsidiary.
  • IRORO Cosmetics Brand Skincare and haircare brand containing proprietary ingredients including CXCL1 hair loss prevention protein and human bone marrow-derived stem cell culture medium. Includes IRORO Nuvon (anti-aging), IRORO AD Intensive Cream (skin barrier), and IRORO DierScalp (haircare) product lines. Trademarks registered in Japan, Korea, and Hong Kong.
  • Enseria (엔세리아) Cosmetics Brand Premium skincare brand launched in February 2025 targeting middle-aged and older consumers with an elegant and sophisticated image, positioned alongside the IRORO brand for a dual-brand global marketing strategy.
  • SCMVial Research Cells Research-use stem cell product using the proprietary Subfractionation Culturing Method. Enables consistent quality cells from basic research through clinical stages for stem cell therapy research applications.
  • Contract Manufacturing (CMO) Services CMO services for bone marrow-derived cell therapy products, including partnerships with CHA Biotech and PBS Biotech for manufacturing process development using the company's 3D Bioreactor mass production technology.

Quantifiable outcome

  • Statistically significant EASI-50 response at Week 12 in moderate-to-severe atopic dermatitis Phase 1/2 trial
  • +2 more outcomes

Companies that use SCM Lifescience

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

SCM Lifescience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

SCM Lifescience partnerships and signals

Strategic signal

Partnerships

18 partnerships are on record, tiered core and minor.

  • Pungjeon Pharmaceutical (풍전약품)coreOthers · 1 July 2025Acquisition completed in July 2025 as part of company's M&A strategy for rapid cGMP and global pipeline expansion.
  • Dermassimo (주식회사 더마시모)coreOthers · 1 July 2025Acquisition completed in July 2025 to expand cosmetics business and secure additional pipeline.
  • Onhill (온힐)coreStrategic or Co-development Partner · 21 January 2025MOU for joint development of pet cell therapy products. Combining SCM Lifescience's stem cell technology with Onhill's pet healthcare platform expertise and market network for innovative cell therapy development for companion animals.
  • Regina Skin Medical Company Ltd.coreChannel Partner/ Reseller/ Distributor · 14 October 2024Chinese state-owned enterprise partnership for exclusive distribution of IRORO cosmetics brand (skincare and haircare products) across China. Initial export contract of approximately 4 billion KRW. Products include CXCL1-based haircare and cell-activated culture media skincare lines.
  • Isblanc (이즈블랑)coreChannel Partner/ Reseller/ Distributor · 1 September 2024Exclusive licensing agreement for IRORO Nuvon newborn skincare products distribution in Japan, with launch preparations underway.
  • Cherry Trading Limited CompanycoreChannel Partner/ Reseller/ Distributor · 1 July 2024Exclusive distribution agreement for all IRORO products in Vietnam. Vietnamese government approval received for cosmetics launch in Ho Chi Minh City and Hanoi.
  • Duopharma Biotech BerhadcoreChannel Partner/ Reseller/ Distributor · 1 July 2024Haircare product supply contract with Malaysian state-owned pharmaceutical company. Halal certification obtained for IRORO products. Distribution through Duopharma Consumer Healthcare subsidiary.
  • Inha University / Inha University HospitalcoreStrategic or Co-development Partner · 1 April 2024Joint business agreement for strategic technology commercialization. Collaboration on autoimmune disease stem cell multi-process platform development (2024 Pan-Ministry Regenerative Medical Technology Development Project).
  • HandokcoreStrategic or Co-development Partner · 1 August 2023Equity investment and license-out contract for severe atopic dermatitis stem cell treatment. Handok expected to announce Phase 3 clinical trial participation decision.
  • PBS BiotechcoreTechnology or Integration · 1 January 2020Partnership for 3D bioreactor mass production process development. Global innovation company for cell therapy manufacturing process achieving groundbreaking cell yield rates.
  • TheraImmuneminorStrategic or Co-development Partner · 1 January 2020MOU for joint development of cell therapy for autoimmune diseases.
  • CoImmune Inc. (USA)coreOthers · 1 January 2020US subsidiary acquired for dendritic cell vaccine and CAR-CIK cell therapy development. FDA-approved Phase 2b trial for metastatic renal cell carcinoma.
  • Formula (Italy)minorOthers · 1 January 2020Italian subsidiary acquired as part of European market expansion through M&A.
  • T&R BiofabminorStrategic or Co-development Partner · 1 January 2019MOU for joint development of 3D bioprinting integrated treatment.
  • Ilya BiologicsminorStrategic or Co-development Partner · 1 January 2019MOU for joint development of high-purity mesenchymal stem cell-derived exosomes.
  • SyntekabiominorStrategic or Co-development Partner · 1 January 2019MOU for joint research on next-generation cell therapy products and biomarkers.
  • ToolgenminorStrategic or Co-development Partner · 1 January 2018MOU for gene-inserted stem cell therapy development.
  • University of UtahcoreStrategic or Co-development Partner · 1 January 2018Joint research agreement for stem cell therapy using cell sheet technology. NIMS Award 2022 recipient for tissue engineering research using SCM's source technology.

Scale indicators5 records

Recent moves8 records

Expansion highlights7 records

SCM Lifescience competitors and assessment

Company assessment

Direct peers

  • Medipost: Korean biotech commercializing Cartistem (allogeneic MSC therapy for knee cartilage) and PneumoStem. Directly comparable as a Korean MSC therapy company with similar regulatory pathway, customer base (hospitals), and orphan/rare disease focus.
  • Corestem: Korean biotech developing Neuronata-R (autologous bone marrow MSC therapy for ALS). Direct peer with same source material (bone marrow-derived MSCs), Korean regulatory focus, and rare intractable disease positioning.
  • Mesoblast: Australian commercial-stage MSC therapy company with Remestemcel-L for pediatric SR-aGVHD and Revascor for heart failure. Closest international peer with comparable allogeneic MSC platform, GVHD indication overlap, and regulatory/clinical pathway.
  • Pluristem Therapeutics: Israel-based company developing PLX cell therapy products from placenta-derived mesenchymal-like adherent stromal cells. Comparable allogeneic, off-the-shelf cell therapy approach targeting inflammatory and ischemic conditions with similar licensing-based commercialization model.
  • Cynata Therapeutics: Australian clinical-stage company developing CYP-001 and other iPSC-derived MSC therapies for GvHD and osteoarthritis. Comparable allogeneic MSC platform with similar disease focus and partnership-driven development model.
  • Athersys: US-based clinical-stage company developing MultiStem (allogeneic bone marrow-derived MSC therapy) for stroke, ARDS, and GvHD. Direct peer with comparable source material, allogeneic platform, and overlapping GvHD indication.
  • Kangstem Biotech: Korean biotech developing stem cell therapies including osteoarthritis and atopic dermatitis applications. Direct Korean peer with overlapping MSC-derived therapies and similar consumer/clinical cosmetics hybrid business model.
  • CHA Biotech: Korean biotech with stem cell and cord blood banking operations, CMO services, and CAR-T pipeline. SCM's CMO partner and most operationally comparable Korean cell therapy company with similar manufacturing focus.
  • Adaptimmune: US-based clinical-stage cell therapy company developing SPEAR T-cell receptor therapies for solid tumors. Comparable to SCM's CoImmune-acquired CARCIK-CD19 and CMN-001 programs in cell-based cancer immunotherapy approach.

Broad incumbents

  • Celltrion: South Korea's largest biopharmaceutical company, biosimilars leader, with expanding cell therapy and biosimilar pipeline. Established Korean biopharma incumbent providing market context, comparable regulatory environment, and potential as a strategic acquirer or partner.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

SCM Lifescience social profiles

Digital presence

SCM Lifescience compliance and trust

Trust signal

Compliance1 record

SCM Lifescience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SCM Lifescience leadership team

Management profile

Number of profiles

Profiles4 records

SCM Lifescience subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

SCM Lifescience funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SCM Lifescience M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SCM Lifescience

What does SCM Lifescience do?

SCM Lifescience develops and supplies high-purity, high-efficacy allogeneic stem cell therapies for intractable diseases including atopic dermatitis (SCM-AGH), acute pancreatitis (SCM-AGH), and chronic graft-versus-host disease (SCM-CGH), plus immune cell therapies (CARCIK-CD19, CMN-001) via its CoImmune subsidiary. The company also operates consumer cosmeceutical brands IRORO and Enseria featuring stem cell culture media and CXCL1 protein ingredients, and provides contract manufacturing (CMO) services for cell therapy products.

Is SCM Lifescience a public or private company?

SCM Lifescience is a public company. It is classified as public and is currently operating.

When was SCM Lifescience founded?

SCM Lifescience was founded in 2014. It employs 11 to 50 people.

Where is SCM Lifescience based?

SCM Lifescience is headquartered in Incheon, South Korea, in the Asia region.

How does SCM Lifescience make money?

Three revenue lines are on record. Stem Cell Therapy Licensing is the primary driver. The others are cosmetic Products and contract Manufacturing (CMO).

Who are SCM Lifescience's main competitors?

Direct peers on record are Medipost, Corestem, Mesoblast, Pluristem Therapeutics, Cynata Therapeutics, Athersys, Kangstem Biotech, CHA Biotech and Adaptimmune. Celltrion is listed as a broad incumbent.

Does SCM Lifescience have an API?

No public API is recorded for SCM Lifescience.

What industry is SCM Lifescience in?

SCM Lifescience's product category is Biopharmaceutical Cell Therapy. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comAcute Pancreatitis Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsightDelveInsight released a 2026 pipeline report on Acute Pancreatitis treatments, identifying four or more companies developing therapies including Panafina, CalciMedica, SCM Lifescience, Pfizer, Repligen Corporation, and Regeneron Pharmaceuticals. The report covers pipeline drugs in various clinical trial phases including Phase III, Phase II, Phase I, and pre-clinical stages. In April 2024, CalciMedica completed patient enrollment for its Phase IIb CARPO clinical trial evaluating Auxora for acute pancreatitis treatment.openPR.comEczema Pipeline Outlook Report 2024 | LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, AstraZeneca, Kyowa Kirin, and OthersDelveInsight released its "Eczema Pipeline Insight 2024" report, providing an analysis of over 100 companies and pipeline drugs in the atopic dermatitis treatment landscape. The report highlights key industry players such as LEO Pharma, GlaxoSmithKline, and AstraZeneca, noting specific clinical trial developments like LEO Pharma's Phase 3 study for Tralokinumab. It categorizes therapies by development stage, mechanism of action, and route of administration to offer a comprehensive view of current market drivers.The Korea HeraldSCM Lifescience lowers IPO price in second attemptSCM Lifescience lowered its IPO price range to 14,000-17,000 won, aiming to raise 30.6 billion won. The biotech firm plans to use proceeds for R&D, clinical tests, and manufacturing facilities. It will submit a clinical test plan for COVID-19 drugs soon.